TY - JOUR
AU - Joven,, Jorge
AB - Familial combined hyperlipidemia (FCHL) is the commonest form of hereditary hyperlipidemia (1) (2). Its primary defect is increased secretion of hepatic triglyceride (TG)-rich apolipoprotein B (apo B)-containing particles (VLDL) (3) and impaired clearance of postprandial lipoproteins (4), which increases the number of circulating TG-rich lipoproteins. FCHL is present in up to 20% of survivors of myocardial infarction, and it is considered a significant genetic risk factor for developing cardiovascular disease (1) (5). The underlying genetic defect is unknown, although the disease has been linked to chromosomes 1 (6) and 11 (7). With regard to the latter, linkage has been identified in the AI-CIII-AIV cluster, encoded in chromosome 11q23-q24, which has been repeatedly associated with FCHL as a site involved in modulating expression of the disease (8) (9). This is in part explained by the role of apo C-III as a negative regulator of TG hydrolysis. Despite considerable effort, no functional variant has been detected that explains such modulatory action, and the search has been extended to the surrounding regions. In this context, the newly identified apo AV gene (APOAV) (10) (11), adjacent to the AI-CIII-AIV gene cluster and with a clear impact on TG metabolism in animals (10), becomes a candidate. Association of this gene with plasma TG concentrations has also been reported in humans (10). We have explored such an association in FCHL. According to the nomenclature and methodology used by Pennacchio et al. (10), single-nucleotide polymorphism C/T number 3 (SNP3; 1 is the common allele, 2 is the rare allele) was used as the genetic marker. Genotyping was performed with primers AV-1 (5′-GATTGATTCAAGATGCATTTAGGAC-3′) and AV-2 (5′-CCCCAGGAACTGGAGCGAAATT-3′), which forced a MseI (New England Biolabs) site for enzymatic restriction. Associations were analyzed between the APOAV gene and TG metabolism in a population-based Spanish control group (12) (ESP controls; n = 408), a normolipidemic control group from The Netherlands (13) (NL controls; n = 89), and 16 FCHL families (9) (n = 103) with 42 hyperlipidemic and 61 normolipidemic first-degree relatives. Normolipidemic controls were selected on the basis of fasting normolipidemia (fasting plasma cholesterol and/or TGs below the 90th percentile) and normoglycemia with negative family history of diabetes, hyperlipidemia, and premature atherosclerosis. In the FCHL families, all index individuals were on lipid-lowering diets and were free of medication for a period of at least 2 months before blood sampling. At inclusion in the study, hyperlipidemic relatives were identified on the basis of the one lipid measurement if they presented with plasma cholesterol concentrations ≥6.4 mmol/L and/or plasma TGs ≥2.8 mmol/L or increased above the 95th percentile for age and gender in the case of offspring below the age of 19 years. Relatives who did not meet these criteria were assigned the normolipidemic status. All individuals recruited into the study gave fully informed written consent, and the protocol was approved by the local Ethical Committees. Among the FCHL families, there was a significant association between the APOAV marker and TG-related variables, but when adjusted for age, gender, body mass index, or diet, these associations were not significant in the control ESP group or the normolipidemic NL group (Table 1). Thus, the influence of APOAV on plasma TGs in the general population appears to be fairly limited. In contrast, a much more pronounced effect was seen in FCHL families, among which carriers of the rare allele presented with 30% higher plasma TGs (P = 0.004), 61% higher VLDL-TG (P = 0.008), and 30% higher intermediate-density lipoprotein-TG (P = 0.007). VLDL-cholesterol (34%; P = 0.049) and VLDL-apo B (33%; P = 0.027) were also significantly increased. This fact suggested that APOAV modulates TG concentrations only when there is an altered genetic and metabolic background. To further confirm this point, we analyzed the association between APOAV and TGs in FCHL hyperlipidemic (n = 42) and normolipidemic (n = 61) individuals separately. FCHL hyperlipidemic patients, carriers of the rarer APOAV allele, presented with significantly increased plasma TG concentrations compared with carriers of the common allele [mean (SD), 2.52 (1.34) vs 1.76 (0.90) mmol/L, respectively; P = 0.017], whereas such an association was not present among the FCHL normolipidemic relatives [0.82 (0.47) vs 0.94 (0.44) mmol/L, respectively]. This suggested a potential implication of APOAV in the hypertriglyceridemia present in FCHL. This point was further supported by the fact that the frequency of the APOAV variant was significantly (P = 0.028) greater among the FCHL patients than in their relatives (Fig. 1). The frequency of the APOAV variant was 2.7-fold higher in hyperlipidemic FCHL patients than in their normolipidemic relatives and 2-fold higher than in the general population (control ESP; Fig. 1). Figure 1. Open in new tabDownload slide APOAV SNP3 genotype (A) and allele (B) frequencies by group. FCHL NL, normolipidemic FCHL relative; FCHL HY, hyperlipidemic FCHL relative; ESP, population-based Spanish control group; NL, normolipidemic control group. a SNP3 rare allele genotypes were significantly more frequent in hyperlipidemic FCHL individuals than in normolipidemic FCHL individuals (P = 0.028). b,c SNP3 rare allele frequency was significantly higher in the hyperlipidemic FCHL group than in the b ESP control group (P = 0.009) and the c group of normolipidemic FCHL relatives (P = 0.019). Figure 1. Open in new tabDownload slide APOAV SNP3 genotype (A) and allele (B) frequencies by group. FCHL NL, normolipidemic FCHL relative; FCHL HY, hyperlipidemic FCHL relative; ESP, population-based Spanish control group; NL, normolipidemic control group. a SNP3 rare allele genotypes were significantly more frequent in hyperlipidemic FCHL individuals than in normolipidemic FCHL individuals (P = 0.028). b,c SNP3 rare allele frequency was significantly higher in the hyperlipidemic FCHL group than in the b ESP control group (P = 0.009) and the c group of normolipidemic FCHL relatives (P = 0.019). Table 1. Effect of APOAV on TGs according to population type.1 Group2 . n . Age, years . % males . BMI,3 kg/m2 . TGs, mmol/L . Cholesterol, mmol/L . HDL-C, mmol/L . apo B-100, g/L . Control NL  Total 89 33.9 (12.1) 54 22.7 (2.3) 0.88 (0.43) 4.51 (0.93) 1.35 (0.29) 8.4 (2.5)  1/1 76 34.5 (12.5) 54 22.7 (2.3) 0.88 (0.44) 4.49 (0.95) 1.36 (0.28) 8.3 (2.6)  1/2 13 30.4 (9.1) 54 22.5 (2.3) 0.90 (0.42) 4.60 (0.82) 1.26 (0.34) 8.8 (2.5) Control ESP  Total 408 41.9 (15.2) 51 26.8 (5.0) 1.31 (0.80) 5.27 (1.03) 1.53 (0.38) NA  1/1 355 41.8 (15.3) 51 26.9 (5.1) 1.29 (0.76) 5.26 (1.00) 1.55 (0.38) NA  1/2 + 2/24 53 42.5 (14.2) 51 26.3 (4.5) 1.49 (1.06)5 5.26 (1.18) 1.45 (0.38) NA FCHL  Total 103 34.8 (21.3) 50 24.6 (5.1) 1.35 (0.92) 5.14 (1.24) 1.16 (0.29) 9.1 (3.1)  1/1 86 33.4 (20.6) 48 24.2 (5.0) 1.26 (0.75) 5.06 (1.24) 1.15 (0.29) 8.8 (3.1)  1/2 + 2/24 17 42.3 (23.9) 65 26.6 (5.3) 1.82 (1.33)6 5.52 (1.19) 1.16 (0.34) 10.2 (3.2) Group2 . n . Age, years . % males . BMI,3 kg/m2 . TGs, mmol/L . Cholesterol, mmol/L . HDL-C, mmol/L . apo B-100, g/L . Control NL  Total 89 33.9 (12.1) 54 22.7 (2.3) 0.88 (0.43) 4.51 (0.93) 1.35 (0.29) 8.4 (2.5)  1/1 76 34.5 (12.5) 54 22.7 (2.3) 0.88 (0.44) 4.49 (0.95) 1.36 (0.28) 8.3 (2.6)  1/2 13 30.4 (9.1) 54 22.5 (2.3) 0.90 (0.42) 4.60 (0.82) 1.26 (0.34) 8.8 (2.5) Control ESP  Total 408 41.9 (15.2) 51 26.8 (5.0) 1.31 (0.80) 5.27 (1.03) 1.53 (0.38) NA  1/1 355 41.8 (15.3) 51 26.9 (5.1) 1.29 (0.76) 5.26 (1.00) 1.55 (0.38) NA  1/2 + 2/24 53 42.5 (14.2) 51 26.3 (4.5) 1.49 (1.06)5 5.26 (1.18) 1.45 (0.38) NA FCHL  Total 103 34.8 (21.3) 50 24.6 (5.1) 1.35 (0.92) 5.14 (1.24) 1.16 (0.29) 9.1 (3.1)  1/1 86 33.4 (20.6) 48 24.2 (5.0) 1.26 (0.75) 5.06 (1.24) 1.15 (0.29) 8.8 (3.1)  1/2 + 2/24 17 42.3 (23.9) 65 26.6 (5.3) 1.82 (1.33)6 5.52 (1.19) 1.16 (0.34) 10.2 (3.2) 1 All values are expressed as the mean (SD). 2 Control NL, normolipidemic control group; ESP, population-based Spanish control group; 1/1, homozygous for the common SNP3 allele; 1/2 + 2/2, heterozygous or homozygous for the rare SNP3 allele. 3 BMI, body mass index; HDL-C, HDL-cholesterol; NA, not available. 4 There was only one 2/2 individual. 5 1/2 + 2/2 vs 1/1 control ESP individuals: P = 0.063. 6 1/2 + 2/2 vs 1/1 control FCHL individuals: P = 0.004. Open in new tab Table 1. Effect of APOAV on TGs according to population type.1 Group2 . n . Age, years . % males . BMI,3 kg/m2 . TGs, mmol/L . Cholesterol, mmol/L . HDL-C, mmol/L . apo B-100, g/L . Control NL  Total 89 33.9 (12.1) 54 22.7 (2.3) 0.88 (0.43) 4.51 (0.93) 1.35 (0.29) 8.4 (2.5)  1/1 76 34.5 (12.5) 54 22.7 (2.3) 0.88 (0.44) 4.49 (0.95) 1.36 (0.28) 8.3 (2.6)  1/2 13 30.4 (9.1) 54 22.5 (2.3) 0.90 (0.42) 4.60 (0.82) 1.26 (0.34) 8.8 (2.5) Control ESP  Total 408 41.9 (15.2) 51 26.8 (5.0) 1.31 (0.80) 5.27 (1.03) 1.53 (0.38) NA  1/1 355 41.8 (15.3) 51 26.9 (5.1) 1.29 (0.76) 5.26 (1.00) 1.55 (0.38) NA  1/2 + 2/24 53 42.5 (14.2) 51 26.3 (4.5) 1.49 (1.06)5 5.26 (1.18) 1.45 (0.38) NA FCHL  Total 103 34.8 (21.3) 50 24.6 (5.1) 1.35 (0.92) 5.14 (1.24) 1.16 (0.29) 9.1 (3.1)  1/1 86 33.4 (20.6) 48 24.2 (5.0) 1.26 (0.75) 5.06 (1.24) 1.15 (0.29) 8.8 (3.1)  1/2 + 2/24 17 42.3 (23.9) 65 26.6 (5.3) 1.82 (1.33)6 5.52 (1.19) 1.16 (0.34) 10.2 (3.2) Group2 . n . Age, years . % males . BMI,3 kg/m2 . TGs, mmol/L . Cholesterol, mmol/L . HDL-C, mmol/L . apo B-100, g/L . Control NL  Total 89 33.9 (12.1) 54 22.7 (2.3) 0.88 (0.43) 4.51 (0.93) 1.35 (0.29) 8.4 (2.5)  1/1 76 34.5 (12.5) 54 22.7 (2.3) 0.88 (0.44) 4.49 (0.95) 1.36 (0.28) 8.3 (2.6)  1/2 13 30.4 (9.1) 54 22.5 (2.3) 0.90 (0.42) 4.60 (0.82) 1.26 (0.34) 8.8 (2.5) Control ESP  Total 408 41.9 (15.2) 51 26.8 (5.0) 1.31 (0.80) 5.27 (1.03) 1.53 (0.38) NA  1/1 355 41.8 (15.3) 51 26.9 (5.1) 1.29 (0.76) 5.26 (1.00) 1.55 (0.38) NA  1/2 + 2/24 53 42.5 (14.2) 51 26.3 (4.5) 1.49 (1.06)5 5.26 (1.18) 1.45 (0.38) NA FCHL  Total 103 34.8 (21.3) 50 24.6 (5.1) 1.35 (0.92) 5.14 (1.24) 1.16 (0.29) 9.1 (3.1)  1/1 86 33.4 (20.6) 48 24.2 (5.0) 1.26 (0.75) 5.06 (1.24) 1.15 (0.29) 8.8 (3.1)  1/2 + 2/24 17 42.3 (23.9) 65 26.6 (5.3) 1.82 (1.33)6 5.52 (1.19) 1.16 (0.34) 10.2 (3.2) 1 All values are expressed as the mean (SD). 2 Control NL, normolipidemic control group; ESP, population-based Spanish control group; 1/1, homozygous for the common SNP3 allele; 1/2 + 2/2, heterozygous or homozygous for the rare SNP3 allele. 3 BMI, body mass index; HDL-C, HDL-cholesterol; NA, not available. 4 There was only one 2/2 individual. 5 1/2 + 2/2 vs 1/1 control ESP individuals: P = 0.063. 6 1/2 + 2/2 vs 1/1 control FCHL individuals: P = 0.004. Open in new tab Altogether these data suggest that in FCHL families, carriers of at least one rare APOAV allele will have a 3.25-fold higher risk (95% confidence interval for the odds ratio, 1.10–9.65) of presenting with the hyperlipidemic phenotype. Once the influence of gender, age, body mass index, and food intake on plasma TG concentrations in these individual is considered, the APOAV genotype could explain up to 30% of the variability observed. Pennacchio et al. (10) reported negative linkage disequilibrium between markers of the AI-CIII-AIV gene cluster and APOAV, indicating an independent effect of APOAV on plasma TG concentrations. We have also analyzed by means of ANOVA the interaction between APOAV and a marker of the apo C-III gene (APOCIII) with a significant TG-increasing effect in FCHL patients (C1100T; exon 3) (9) and detected a significant interaction (P = 0.012) between the two. This allows us to speculate that certain haplotypes of APOAV and AI-CIII-AIV might act independently but with additive effects in increasing TG concentrations in FCHL. It is difficult to speculate about the mechanism by which apo AV contributes to FCHL because very little is known about the protein encoded by APOAV. apo AV is associated with the VLDL and HDL fractions (10) (11), and the mechanism by which apo AV dramatically influences TG concentrations in transgenic and knock-out mice remains unknown (10). Even more recently, apo AV has been linked to liver regeneration in the rat (11). van der Vliet et al. (11) speculated that apo AV might antagonize lipid uptake by the liver, which could explain the association of APOAV with plasma TGs. Functional characterization of apo AV is required before we can understand the observed associations and gain new insight into the causes of FCHL. However, the fact that APOAV is associated with increased VLDL-apo B but not with total or LDL-apo B suggests that apo AV might be involved in the delay of peripheral TG hydrolysis. At present we report that the polymorphic marker SNP3 of APOAV is overrepresented in FCHL and can be considered as a predisposing factor for this condition. Because of the size of the FCHL group, these results should be considered preliminary. FCHL is a condition associated with cardiovascular risk; therefore, further studies will be necessary to explore whether APOAV is a new candidate marker for cardiovascular disease. Whether such a variant is causative or is in linkage disequilibrium with the actual functional mutation also remains to be studied. We have also shown that the association of APOAV with increased TGs in the general population is limited and completely absent in individuals selected as normolipidemic. 1 " these authors contributed equally to this work; We acknowledge Carme Arbós for excellent technical assistance. This work was supported by grants from Fondo de Investigación Sanitaria (References 99/0945, 00/0954, and 01/1596). J.R. is a researcher of the Ramón y Cajal Programe from the Spanish Ministry of Science and Technology. L.F. is a recipient of a predoctoral fellowship at the Insitut de Recerca en Ciències de la Salut (IRCIS) Foundation. References 1 Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973 ; 52 : 1544 -1568. Crossref Search ADS PubMed 2 Sniderman AD, Castro Cabezas M, Ribalta J, Carmena R, de Bruin TWA, de Graaf J, et al. A proposal to redefine familial combined hyperlipidemia. Eur J Clin Invest 2002 ; 32 : 71 -73. Crossref Search ADS PubMed 3 Janus ED, Nicoll AM, Turner PR, Magill P, Lewis B. Kinetic bases of the primary hyperlipidemias: studies of apolipoprotein B turnover in genetically defined subjects. Eur J Clin Invest 1980 ; 10 : 161 -172. Crossref Search ADS PubMed 4 Castro Cabezas M, de Bruin TWA, Jansen H, Kock AW, Kortland W, Erkelens DW. Impaired chylomicron remnant clearance in familial combined hyperlipidemia. Arterioscler Thromb 1993 ; 13 : 804 -814. Crossref Search ADS PubMed 5 Austin MA, McKnight B, Edwards KL, Bradley CM, McNeely MJ, Psaty BM, et al. Cardiovascular disease mortality in familial forms of hypertriglyceridemia. Circulation 2000 ; 101 : 2777 -2782. Crossref Search ADS PubMed 6 Pajukanta P, Nuotio I, Terwilliger JD, Porkka KVK, Ylitalo K, Pihlajamäki J, et al. Linkage of familial combined hyperlipidemia to chromosome 1q21–q23. Nat Genet 1998 ; 18 : 369 -373. Crossref Search ADS PubMed 7 Wojciechowski AP, Farrall M, Cullen P, Wilson TM, Bayliss JD, Farren B, et al. Familial combined hyperlipidaemia linked to the apolipoprotein AI-CIII-AIV gene cluster on chromosome 11q23–q24. Nature 1991 ; 349 : 161 -164. Crossref Search ADS PubMed 8 Dallinga-Thie GM, van Linde-Sibenius Trip M, Rotter J, Cantor RM, Bu X, Lusis AJ, et al. Complex genetic contribution of the Apo AI-CIII-AIV gene cluster to familial combined hyperlipidemia. J Clin Invest 1997 ; 99 : 953 -961. Crossref Search ADS PubMed 9 Ribalta J, La Ville AE, Vallvé JC, Humphries SE, Turner PR, Masana L. A variation in the apolipoprotein C-III gene is associated with an increased number of circulating VLDL and IDL particles in familial combined hyperlipidemia. J Lipid Res 1997 ; 38 : 1061 -1069. PubMed 10 Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 2001 ; 294 : 169 -173. Crossref Search ADS PubMed 11 van der Vliet HN, Groenink Sammels M, Leegwater ACJ, Levels JHM, Reitsma PH, Boers W, et al. Apolipoprotein V. J Biol Chem 2001 ; 276 : 44512 -44520. Crossref Search ADS PubMed 12 Murphy M, Vilella E, Ceruelo S, Figuera L, Sánchez M, Camps J, et al. The MTHFR C677T, APOE, and PON55 polymorphisms show relevant interactions with cardiovascular risk factors. Clin Chem 2002 ; 48 : 372 -375. PubMed 13 Castro Cabezas M, Halkes CJM, Meijssen S, van Oostrom AJHHM, Erkelens DW. Diurnal triglyceride profiles: a novel approach to study triglyceride changes. Atherosclerosis 2001 ; 155 : 219 -228. Crossref Search ADS PubMed © 2002 The American Association for Clinical Chemistry This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
TI - Newly Identified Apolipoprotein AV Gene Predisposes to High Plasma Triglycerides in Familial Combined Hyperlipidemia
JO - Clinical Chemistry
DO - 10.1093/clinchem/48.9.1597
DA - 2002-09-01
UR - https://www.deepdyve.com/lp/oxford-university-press/newly-identified-apolipoprotein-av-gene-predisposes-to-high-plasma-2Pm7RhRW90
SP - 1597
VL - 48
IS - 9
DP - DeepDyve
ER -